Clinical
CellCentric is focused on developing inobrodib to transform cancer treatment outcomes for maximum benefit to patients, as fast as possible
Inobrodib has a broad spectrum of potential applications due to its mechanism of action - strong pre-clinical and clinical data support its use in treating multiple indications.
Different cancer indications can be targeted by inobrodib as a monotherapy or in combination with existing standard of care drugs
Late stage prostate cancer - metastatic Castration Resistant Prostate Cancer (mCRPC)
Haematological cancers - Relapsed/refractory haematological cancers including Acute Myeloid Leukemia (AML), Multiple Myeloma (MM) and Diffuse Large B-cell Lymphoma (DLBCL)
Tumours driven by specific genomic alterations – inobrodib can specifically target tumours with amplified Myc or Androgen Receptor (AR), bearing ARID1A mutations or tumours with p300/CBP loss of function mutations.
Identification of further relevant cancer types is ongoing – e.g. lung, breast, salivary duct
Haematological cancers - Relapsed/refractory haematological cancers including Acute Myeloid Leukemia (AML), Multiple Myeloma (MM) and Diffuse Large B-cell Lymphoma (DLBCL)
Tumours driven by specific genomic alterations – inobrodib can specifically target tumours with amplified Myc or Androgen Receptor (AR), bearing ARID1A mutations or tumours with p300/CBP loss of function mutations.
Identification of further relevant cancer types is ongoing – e.g. lung, breast, salivary duct
Inobrodib is a first-in-class oral anti-cancer with a new mechanism of action through targeting twin tumour drivers, p300/CBP
Targeting the transcriptional regulation of key oncogenes, including Myc and the Androgen Receptor. Inobrodib binds selectively into the conserved bromodomain of p300 and CBP; it is distinct from BET inhibitors. Its action has been shown to be synergistic with BET inhibitors, whilst impacting the expression of 7x fewer genes (compared to JQ1).
Targets:
1. All variant forms of the Androgen Receptor; particularly important for therapy-induced mCRPC
2. Myc-dependent tumours; for which there are few treatment options
3. IRF4; a driver mutation in multiple myeloma and other haematological cancers
4. Can affect immunomodulators such as PD-L1
Targets:
1. All variant forms of the Androgen Receptor; particularly important for therapy-induced mCRPC
2. Myc-dependent tumours; for which there are few treatment options
3. IRF4; a driver mutation in multiple myeloma and other haematological cancers
4. Can affect immunomodulators such as PD-L1
Phase I/II clinical trials
CellCentric’s clinical programme reflects the mechanism of action of p300/CBP inhibition. Inobrodib is being evaluated in three parallel strands. Each represents significant and growing clinical unmet needs.
Patient enrolment
Potential suitability for enrolment in an inobrodib clinical trial will be made by oncologists at our participating hospitals, and not by CellCentric. Any advice on clinical study options should come from your general practitioner and/or oncologist.